Multi-organ failure after acute kidney injury in patient with HIV and COVID-19

M. Elhadi¹, A. A. Momen², O. M. A. S. Abdulhadi² and A. Msherghi¹
¹) Faculty of Medicine, University of Tripoli and 2) Alhadba Alkhadra Hospital, Tripoli, Libya

Abstract

We describe the first death in Libya from coronavirus disease 2019 (COVID-19) presenting as acute kidney failure in an 86-year-old woman in Tripoli with no recent travel history. She had a history of type 2 diabetes mellitus and human immunodeficiency virus (HIV) infection, for which she reported non-compliance with treatment. On 15 March 2020, she was diagnosed with lobar pneumonia and her condition did not improve. On 30 March she presented to Tripoli University Hospital Emergency Department with a cough, temperature of 39°C, respiratory rate of 24 breaths/min, pulse of 110 beats/min and blood pressure of 130/80 mmHg. Nasopharyngeal swab and sputum were negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on real-time RT-PCR. On 1 April 2020, the patient's status deteriorated and she was diagnosed with acute kidney injury as a complication of sepsis, with a urea level of 240 mg/dL (reference range 5–50 mg/dL) and creatinine level of 7.69 mg/dL (reference range 0.4–1.3 mg/dL). She was referred for dialysis at Tripoli University Hospital on 2 April. However, the patient died, despite attempted resuscitation, from multiple organ dysfunction syndrome following acute kidney injury. A nasopharyngeal swab and sputum were collected, which were positive for SARS-CoV-2 on real-time RT-PCR. This case provides an insight into the importance of testing for SARS-CoV-2, in the context of an epidemic in all patients with atypical presentation, particularly those with associated HIV infection.

Keywords: Coronavirus disease 2019, human immunodeficiency virus, outbreak, pneumonia, severe acute respiratory syndrome coronavirus 2

Original Submission: 12 June 2020; Revised Submission: 29 June 2020; Accepted: 5 August 2020
Article published online: 11 August 2020

Background

A novel coronavirus was reported as the source of severe viral pneumonia in Wuhan, Hubei Province, China at the end of December 2019 [1,2]. Since then, it has spread exponentially, contributing to a pandemic that has led to >6 million documented cases of coronavirus disease 2019 (COVID-19) reported to the WHO, including >373 000 deaths as of 1 June 2020 [3–5]. We describe the first confirmed fatal case of COVID-19 in Libya.
which were negative for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) on real-time RT-PCR at the Na-
tional Centre for Disease Control in Tripoli. After that, the
patient was sent home and advised to continue her treatment.

On 1 April 2020, she presented to Abu-Seta Respiratory
Outpatient Clinic because of worsening cough, dyspnoea, head-
ache and fever. However, the patient was referred to Alhadba
Alkhadra Hospital by Abu-Seta Respiratory Outpatient Clinic,
which refused to admit her because of a shortage of facilities. On
admission to the hospital on 1 April 2020, her temperature was
38.5°C, respiratory rate 20 breaths/min, pulse 115 beats/min,
blood pressure 100/60 mmHg and oxygen saturation 77% on
room air. High-resolution CT showed lung infiltration, collapsed
left lung due to underlying lung fibrosis, and ground-glass opac-
ities in both lungs, mostly in the lower zone, with a peripheral
subpleural distribution (Fig. 1). The patient was placed on
continuous positive airway pressure in the intensive care unit
despite the suspicion of COVID-19 after high-resolution CT.

Complete blood counts were: lymphocyte count 0.40 × 10⁹/L
(reference range 1.0 × 10⁹ to 4.0 × 10⁹/L); white blood cell
count 10.8 × 10⁹/L; platelet count 98 × 10⁹/L and haemoglobin
concentration 13.1 g/dL. Liver function test abnormalities were:
alkaline phosphatase 198 U/L (reference range 40–129 U/L);
normal alanine aminotransferase 15 U/L (reference range 5–41
U/L) and aspartate aminotransferase 45 U/L (reference range
5–43 U/L). Lactate dehydrogenase test abnormalities peaked
on admission day at 1200 U/L (reference range 120–300 U/L);
ferritin 484 ng/L (reference range 30–400 ng/L) and glucose
182 mg/dL (reference range 70–120 mg/dL). C-reactive protein
concentration was 532.2 mg/L (reference range <5 mg/L).

FIG. 1. Radiological findings of high-resolution computed tomography showed lung infiltration, collapsed left lung due to underlying lung fibrosis and ground-glass opacities in both lungs, mostly in the lower zone, with a peripheral subpleural distribution.
On 1 April 2020, the patient’s status deteriorated and she was diagnosed with acute kidney injury, with a urea level of 240 mg/dL (reference range 5–50 mg/dL) and creatinine level of 7.69 mg/dL (reference range 0.4–1.3 mg/dL). The patient was referred for dialysis at Tripoli University Hospital on 2 April. However, she died, despite attempted resuscitation, due to multiple organ dysfunction syndrome following acute kidney injury. A nasopharyngeal swab and sputum were collected, which were positive for SARS-CoV-2 on real-time RT-PCR by the National Centre for Disease Control in Tripoli. However, her family members and health-care workers who managed the patient all tested negative for SARS-CoV-2 on RT-PCR. This case raises questions about SARS-CoV-2 transmission and testing capability in Libya.

Discussion and conclusions

Testing for SARS-CoV-2 as reported here is mandatory in any situation to avoid exposing care providers. This needs an important investment in testing capability. Civil war and fragility of the healthcare system are ongoing challenges to Libya’s ability to manage and control COVID-19. Therefore, a surveillance plan is needed in Libya to increase the capacity of the government to detect cases of COVID-19, as the National Centre for Disease Control in Tripoli has a low daily capacity to perform SARS-CoV-2 testing, with a mean daily testing capability of <50 test per day during March and April 2020 [6]. This case also provides an insight into the importance of co-infection between HIV and SARS-CoV-2. Immunocompromised patients may be at higher risk of complications and deterioration due to COVID-19 infection. Finally, physicians in charge of such patients should be aware that antiretroviral therapy for HIV-positive individuals does not seem to prevent COVID-19, especially those on lopinavir-ritonavir [7]. Also, we should emphasize that relying on PCR for diagnosis carries the risk of delaying treatment and management of suspected cases of COVID-19. This case provides an insight into the importance of testing for SARS-CoV-2, in the context of an epidemic, all patients with atypical presentations particularly those with associated HIV infection.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Image is entirely unidentifiable, and there are no details on individuals reported within the manuscript, consent for publication of images may not be required.

Availability of data and materials

All data and report are available upon request.

Transparency declaration

The authors declare that they have no competing interests and no relationship with the industry.

Funding

This study did not receive any grant or funding from any department or institute.

Authors’ contributions

Conceptualization and data curation were by ME, AMo and OA. Formal analysis was by ME and investigation by ME, AMo, OA and AMs. ME and AMs wrote the original draft and ME, AMo, OA and AMs reviewed and edited the article.

Acknowledgements

Not applicable.

References

[1] World Health Organization. Pneumonia of unknown cause. Available at: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/. 2020.
[2] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395(10223):514–23.
[3] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—17-april-2020. 2020; 17 April 2020.
[4] Elhadi M, Momen AA, Ali Sennussi Abdulhadi OM. A COVID-19 case in Libya acquired in Saudi Arabia. Travel Med Infect Dis 2020:101705.
[5] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533–4.
[6] Elhadi M, Mshergi A. COVID-19 and civil war in Libya: the current situation. Pathogens Glob Health 2020:1–2.
[7] Blanco JL, Ambrosioni J, García F, Martínez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020;7. e314–e6.